Biomarkers (1)
- LDH (normal less than 246) - Serum lactate dehydrogenase (phv00258357.v1.p1)
Demographics (2)
- Age - Patient's age (phv00258344.v1.p1)
- Sex - Gender of participant (phv00258346.v1.p1)
Disease Events (3)
- AFFECTION_STATUS - Case control status of the subject. All subjects are patients with melanoma who were treated with ipilimumab or tremelimumab. (phv00258336.v1.p1)
- OS_yr - Overall survival (phv00258359.v1.p1)
- TUMOR_STAGE - Tumor stage of sample (phv00258367.v1.p1)
Other (32)
- Alive - Alive during last assessment (phv00258345.v1.p1)
- ANALYTE_TYPE - Analyte Type (phv00258363.v1.p1)
- Biopsy pre or post ipi - Biopsy status before and after Ipilimumab treatment (phv00258360.v1.p1)
- Biopsy type - Biopsy type (phv00258351.v1.p1)
- BODY_SITE - Location of tumor in study (phv00258362.v1.p1)
- BRAF/NRAS status - BRAF(GeneID: 673)/NRAS(GeneID: 4893) mutations (phv00258358.v1.p1)
- Clinical_Benefit - Long time clinical benefit (phv00258348.v1.p1)
- Cohort - Patient's cohort in current study (phv00258343.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00258333.v1.p1)
- Drug - Drug of treatment (phv00258355.v1.p1)
- EXPRESSION_ANALYSIS_CENTER - Name of the center which conducted genotyping (phv00258369.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00258365.v1.p1)
- Ipi_dosing - Ipilimumab dose (phv00258354.v1.p1)
- IS_TUMOR - Tumor status (phv00258364.v1.p1)
- Largest Dimension (cm) - Largest dimension of tumor (phv00258350.v1.p1)
- Primary Melanoma type - Primary melanoma type (phv00258352.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Primary tumor, metastasis, or transformed cell line (phv00258366.v1.p1)
- Priors - Number of prior therapies (cytotoxic or IL-2) (phv00258347.v1.p1)
- Response duration (weeks) - Response duration in weeks (phv00258356.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00258361.v1.p1)
- SAMPLE_ID - Sample ID (phv00258338.v1.p1)
- SAMPLE_SOURCE - Source repository where samples originate (phv00258339.v1.p1)
- SAMPLE_USE - Sample use. Seq_RNA: Whole transcriptome sequencing; Seq_RNA_Expression: Expression levels derived from RNA sequences (phv00258341.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00258370.v1.p1)
- Site - Location of tumor in study (phv00258349.v1.p1)
- SOURCE_SAMPLE_ID - Sample ID used in the Source Repository (phv00258340.v1.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the source repository (phv00258335.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00258342.v1.p1)
- SUBJECT_ID - Subject ID (phv00258332.v1.p1)
- SUBJECT_ID - Subject ID (phv00258337.v1.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00258334.v1.p1)
- TUMOR_TREATMENT - Type of tumor treatment for sample (phv00258368.v1.p1)